Determining Preferred Product Characteristics to Support Uptake of Innovative Antibodies (360G-Wellcome-220401_Z_20_Z)

Through this project, IAVI and WHO Immunizations, Vaccines, and Biologicals (IVB) will harness input from a broad network of stakeholders to produce a Preferred Product Characteristics (PPC) technical document for forthcoming monoclonal antibodies (mAbs) for HIV prevention. Created early in clinical development and with attentiveness to end-user and health systems perspectives, this PPC document will provide strategic guidance as to preferences for new HIV preventative antibodies to inform clinical development and support eventual integration into WHO policy. While the focus of this effort will be on articulating optimal product attributes for antibodies for HIV prophylaxis, it is anticipated that acceptability, suitability and feasibility criteria identified through this process can inform product design, clinical development, and access considerations for a broader array of antibody-based products for infectious and neglected diseases in the pipeline.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 72206
Applicant Surname Malhotra
Approval Committee Internal Decision Panel
Award Date 2020-09-30T00:00:00+00:00
Financial Year 2019/20
Grant Programme: Title Discretionary Award – Innovations
Internal ID 220401/Z/20/Z
Lead Applicant Ms Shelly Malhotra
Partnership Value 72206
Planned Dates: End Date 2022-11-16T00:00:00+00:00
Planned Dates: Start Date 2020-05-15T00:00:00+00:00
Recipient Org: Country United States
Region International